https://orcid.org/0000-0001-6048-405X
References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
- Synchronous Bilateral Lung Cancer With Discordant Histology. Available from: https://www.cancernetwork.com/lung-cancer/synchronous-bilateral-lung-cancer-discordant-histology. Accessed 1127, 2020.
- Loukeri AA, Kampolis CF, Ntokou A, Tsoukalas G, Syrigos K. Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis. Clin Lung Cancer. 2015;16(1):15–23. doi:10.1016/j.cllc.2014.07.00125246383
- Black RC, Khurshid H. NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance. R I Med J. 2015;98(10):25–28.
- Liu Y, Zhang J, Li L, et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun. 2016;7:13200.27767028
- Luo J, Gu D, Lu H, Liu S, Kong J. Coexistence of a novel PRKCB-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to crizotinib. J Thorac Oncol. 2019;14(12):e266–e268. doi:10.1016/j.jtho.2019.07.02131757376
- Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381. doi:10.1038/nm.265822327623
- Li M, Zhou CZ, Yang JJ, et al. The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients. Cancer Biol Ther. 2019;20(8):1097–1104.30990107
- Facchinetti F, Loriot Y, Kuo MS, et al. Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers. Clin Cancer Res. 2016;22(24):5983–5991. doi:10.1158/1078-0432.CCR-16-091727401242
- Zhu YC, Xu CW, Ye XQ, et al. Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. Onco Targets Ther. 2016;9:4301–4305.27486332
- Ju L, Han M, Zhao C, Li X. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient. Lung Cancer. 2016;95:94–97. doi:10.1016/j.lungcan.2016.03.00527040858
- Mao Y, Wu S. ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma. Onco Targets Ther. 2017;10:3399–3404. doi:10.2147/OTT.S13334928744144
- Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7(6):596–609. doi:10.1158/2159-8290.CD-16-133728336552